BMS-986365 (CC-94676) is an orally available, selective and highly potent AR degrader with potential anticancer activity that inhibits AR signaling and suppresses tumor growth for the study of prostate cancer.
Les produits sont exclusivement destinés à la recherche. Ils ne doivent pas être utilisés chez l’être humain. Nous ne vendons pas aux patients.
| Pack Size | Price | Availability | Quantity | Action |
|---|---|---|---|---|
| 1mg | $218.00 | In Stock | 1 | |
| 5mg | $438.00 | In Stock | 1 | |
| 10mg | $700.00 | In Stock | 1 | |
| 25mg | $1,035.00 | In Stock | 1 | |
| 50mg | $1,404.00 | In Stock | 1 |
BMS-986365 (CC-94676) is an orally available, selective and highly potent AR degrader with potential anticancer activity that inhibits AR signaling and suppresses tumor growth for the study of prostate cancer.
References:
[1]. Xu S, et al. Abstract ND02: Discovery of BMS-986365, a ligand-directed androgen receptor degrader (AR LDD) with a dual mechanism-of-action and best-in-class potential, for the treatment of advanced prostate cancer[J]. Cancer Research, 2024, 84(7_Supplement): ND02-ND02.